Roche Diagnostics has announced a key leadership transition for its India and Neighboring Markets business. Effective August 1, 2026, Marco Valencia Sanchez will assume the role of General Manager, Roche Diagnostics India, succeeding Rishubh Gupta, who has been appointed Head of Subregion Africa for Roche Diagnostics, based in Nairobi, Kenya.
Rishubh Gupta, who joined Roche India in 2023, successfully navigated complex market dynamics and strengthened the organisation’s focus on expanding diagnostic access across India and its neighboring markets. In his new regional role, he will join the Roche Diagnostics EMEA-LATAM leadership team.
Reflecting on his tenure, Gupta shared, “Leading the India and Neighboring Markets team has been an extraordinary privilege. I am deeply proud of the passion, grit, and customer-first mindset our team has demonstrated in making advanced diagnostics more accessible across the region. As I transition to my new role in Africa, I carry immense gratitude for our partners, clinicians, and team members who have been vital to this journey. I am confident that under Marco’s stellar leadership, Roche India will reach even greater heights.”
Sanchez steps into the role of India General Manager with a 17-year career within Roche. Having held key global, regional, and affiliate leadership roles, Marco most recently served as the Country Manager for Roche Diagnostics Philippines for the past four years, driving significant market growth and operational excellence. He will be relocating to Mumbai with his family.
Commenting on his appointment, Sanchez said, “I am honored to step into this role at such a transformative time for the Indian healthcare landscape. The market is experiencing a profound shift, where advanced diagnostic capabilities are becoming central to early intervention and patient outcomes. Building on the strong foundation laid by Rishubh and the team, I am excited by our next chapter. I look forward to deepening our ecosystem partnerships and accelerating the delivery of cutting-edge diagnostics to meet the evolving needs of clinicians and patients across the market.”